Form 4: Enliven CMO Exercises Options, Sells Shares

Enliven Therapeutics' Chief Medical Officer, Helen Louise Collins, exercised stock options and subsequently sold 5,000 shares of common stock under a pre-arranged 10b5-1 trading plan.

Summary

• Helen Louise Collins, Chief Medical Officer of Enliven Therapeutics, Inc., executed transactions on March 17, 2026.
• Exercised options to acquire 5,000 shares of common stock at an exercise price of $2.48 per share.
• Subsequently sold 5,000 shares of common stock at a weighted average price of $27.76 per share.
• The transactions were conducted under a Rule 10b5-1 trading plan adopted on October 19, 2025.
• Following these transactions, Collins beneficially owns 25,000 shares of common stock (comprising Restricted Stock Units) and 176,268 stock options.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. It's a routine insider transaction under a pre-arranged 10b5-1 plan, which typically does not signal a change in company fundamentals or management's confidence.

Positives

• The sale was executed at a significantly higher price ($27.76) than the exercise price ($2.48), indicating a profitable transaction for the insider.
• The transaction was pre-planned under a Rule 10b5-1 plan, which suggests a systematic approach to insider trading rather than opportunistic timing.

Negatives

• An insider sale, even under a 10b5-1 plan, can sometimes be perceived negatively by investors as it reduces the insider's direct equity stake.

Future Outlook

N/A

Industry Context

StockSavvy.ai notes that routine insider transactions, especially those executed under pre-arranged 10b5-1 plans, are common in the biotechnology and pharmaceutical sectors as a means for executives to manage their equity compensation and personal finances while adhering to insider trading regulations. These transactions typically do not reflect a change in the company's operational outlook or strategic direction.

Comparison to Industry Standards

• Insider sales under 10b5-1 plans are a standard practice across industries, including biotechnology, for executives to diversify their holdings and manage liquidity without violating insider trading rules. This is consistent with practices observed at comparable companies like Amgen or Gilead Sciences, where executives frequently utilize such plans for equity compensation.
• The significant difference between the exercise price ($2.48) and the sale price ($27.76) is typical for long-term equity compensation plans in successful growth companies, reflecting the appreciation of the company's stock over time.

Stakeholder Impact

• Shareholders: The sale of shares by a Chief Medical Officer, while routine under a 10b5-1 plan, slightly reduces insider ownership, which some investors might monitor. However, the overall impact is likely minimal given the pre-planned nature.
• Employees: No direct impact on employees is indicated by this filing.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated by this filing.

Key Dates

Recommendation

This Form 4 filing reports a routine insider transaction (option exercise and sale) executed under a pre-arranged 10b5-1 plan. Such transactions are generally neutral events and do not typically provide new fundamental information to warrant a change in investment recommendation. The profitability of the transaction for the insider is positive for the individual but does not inherently change the company's investment thesis. Therefore, a 'hold' recommendation is appropriate as this filing alone does not present a compelling reason to buy or sell.

Keywords

Enliven Therapeutics, ELVN, Form 4, Insider Trading, Stock Option Exercise, Share Sale, Helen Louise Collins, Chief Medical Officer, 10b5-1 Plan, Biotechnology, Pharmaceuticals